SCHEMBL3854935

SCHEMBL3854935

CCCN(CCC)C(=O)c1cc(Cl)ccn1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.77
MAPT P10636 1/20 0.77
L3MBTL1 Q9Y468 1/20 0.77
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
TP53 P04637 1/20 0.45
KDM4C Q9H3R0 1/20 0.44
CNR2 P34972 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
OPRK1 P41145 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HPGD P15428 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16569986 0.83 ALDH1A1 (0.53) ALDH1A1MAPTL3MBTL1TP53KDM4C
SCHEMBL3854386 0.80 KDM5B (0.57) ALDH1A1MAPTL3MBTL1TP53KDM4C
SCHEMBL31607214 0.79 ALDH1A1 (0.74) ALDH1A1MAPTL3MBTL1NPC1RAB9A
SCHEMBL3807628 0.79 ALDH1A1 (0.49) ALDH1A1MAPTL3MBTL1TP53KDM4C
SCHEMBL31029421 0.78 ALDH1A1 (0.68) ALDH1A1MAPTL3MBTL1NPC1RAB9A
SCHEMBL621293 0.78 ALDH1A1 (0.68) ALDH1A1MAPTL3MBTL1NPC1RAB9A
SCHEMBL19404527 0.76 TP53 (0.58) ALDH1A1MAPTL3MBTL1TP53KMT2A
SCHEMBL3853630 0.75 HPGD (0.48) ALDH1A1MAPTL3MBTL1TP53HTT
SCHEMBL27911792 0.75 ALDH1A1 (0.63) ALDH1A1MAPTL3MBTL1NPC1RAB9A
SCHEMBL712142 0.74 ALDH1A1 (0.62) ALDH1A1MAPTL3MBTL1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618978-B2 Amides as BACE inhibitors ELI LILLY AND COMPANY (US) 2009-11-17 US disclosed
US-7585885-B2 Pyrrolidine derivatives useful as BACE inhibitors ELI LILLY AND COMPANY (US) 2009-09-08 US disclosed
US-20070225372-A1 Amides as Bace Inhibitors ELI LILLY AND COMPANY 2007-09-27 US disclosed
US-20070213331-A1 PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS ELI LILLY AND COMPANY 2007-09-13 US disclosed
EP-1740575-A2 PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2007-01-10 EP disclosed
EP-1740573-A1 AMIDES AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2007-01-10 EP disclosed
WO-2005108358-A2 PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2005-11-17 WO disclosed
WO-2005108391-A1 AMIDES AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225372-A1 Amides as Bace Inhibitors BACE2, BACE1, APP ALDH1A1 661/4885MAPT 41/4885L3MBTL1 4137/4885
US-20070213331-A1 PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS BACE1, BACE2, PSEN1 ALDH1A1 1523/4885MAPT 46/4885L3MBTL1 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.